Amgen Inc.AMGN

Healthcare
Neutral

ASignal's systematic analysis rates AMGN as Neutral. Amgen Inc. has a market cap of $193.39B, a P/E of 24.69, a 21.0% net margin, and 5.8% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Jul 16, 2026

The case on AMGN

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Gross margin of 71.44% indicates strong pricing power
  • Forward P/E of 15.29x suggests valuation improvement potential
  • Positive free cash flow of $7.44B
  • Operating cash flow of $10.76B supports financial operations
VS
Bear case
  • Debt-to-equity ratio of 6.24x raises financial risk concerns
  • Current ratio of 1.26x and quick ratio of 0.85x indicate liquidity pressure
  • RSI near neutral but MACD histogram negative, signaling weakening momentum
  • Dividend yield of 284.00% is unsustainable and likely data anomalous

Key facts

Sector
Healthcare
Market cap
$193.39B
P/E ratio
24.69
Gross margin
71.4%
Net margin
21.0%
Rev growth YoY
5.8%
Price (Jul 16, 2026)
$358.32

Peers

Clustered with AMGN by analysis-profile similarity.

Subscriber-only

See the full verdict on AMGN

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes AMGN

Most investors never get a second opinion, let alone several. ASignal runs AMGN past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Amgen Inc. (AMGN) Stock Analysis - ASignal rates it Neutral